

05 July 2024

Eden Research plc

("Eden" or "Company")

Grant of Awards Under Long-Term Incentive Plan

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in global crop protection, animal health and consumer products industries, confirms the grant of options under the Company's Long Term Incentive Plan ("LTIP") to Sean Smith, Chief Executive Officer, and Alex Abrey, Chief Finance Officer (together the "Executives"), as follows:

The Company has made a grant to the Executives, in respect of 2023 in order to ensure continuity of long term incentive, of options over 11,918,901 new Ordinary Shares in Eden ("the Options"), at a strike price of 6.5p each, representing a premium of 48% to the current share price, in the amounts of 6,805,852 awarded to Sean Smith and 5,113,049 awarded to Alex Abrey.

The Options expire on 30 June 2028 and vest as follows:

1/3 12 months from the date of grant

1/3 24 months from the date of grant

1/3 36 months from the date of grant

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail.

For further information contact:

Eden Research plc

Sean Smith

Alex Abrey

www.edenresearch.com

01285 359 555

Cavendish Capital Markets Limited (Nominated advisor and broker)

Giles Balleny / George Lawson (corporate finance)

Michael Johnson (sales)

020 7397 8900

Hawthorn Advisors (Financial PR)

Victoria Ainsworth

eden@hawthornadvisors.com

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Sean Smith
2	Reason for the notification	

a)	Position/status	Chief Executive Officer					
b)	Initial notification /Amendment	Initial Notification					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Eden Research plc					
b)	LEI	213800ZWTYTVQQSM3J85					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of 1 pence each GB0001646941					
b)	Nature of the transaction	Grant of options					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>6.5p</td><td>6,805,852</td></tr></table>	Price(s)	Volume(s)	6.5p	6,805,852	
Price(s)	Volume(s)						
6.5p	6,805,852						
d)	Aggregated information - Aggregated volume - Price	N/A					
e)	Date of the transaction	4 July 2024					
f)	Place of the transaction	Outside of trading venue					

1	Details of the person discharging managerial responsibilities / person closely associated						
a)	Name	Alex Abrey					
2	Reason for the notification						
a)	Position/status	Chief Financial Officer					
b)	Initial notification /Amendment	Initial Notification					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Eden Research plc					
b)	LEI	213800ZWTYTVQQSM3J85					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of 1 pence each GB0001646941					
b)	Nature of the transaction	Grant of options					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>6.5p</td><td>5,113,049</td></tr></table>	Price(s)	Volume(s)	6.5p	5,113,049	
Price(s)	Volume(s)						
6.5p	5,113,049						
d)	Aggregated information - Aggregated volume - Price	N/A					
e)	Date of the transaction	4 July 2024					

f)	Place of the transaction	Outside of trading venue
----	--------------------------	--------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSSLFWLELSESW